BriaCell Therapeutics

About:

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

Website: http://briacell.com/

Twitter/X: briacell

Top Investors: Prevail Partners

Description:

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. The company's patented immunotherapy Bria-IMT™ is developed from a breast cancer cell line is an immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. It induces an antitumor response both indirectly and directly by stimulating the immune system which collectively boosts the body’s response. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in a combination with retifanlimab and epacadostat. The company is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for advanced breast cancer. It is founded in New York, New York in 2004.